ZA200506549B - A low dose corticosteroid composition - Google Patents
A low dose corticosteroid composition Download PDFInfo
- Publication number
- ZA200506549B ZA200506549B ZA200506549A ZA200506549A ZA200506549B ZA 200506549 B ZA200506549 B ZA 200506549B ZA 200506549 A ZA200506549 A ZA 200506549A ZA 200506549 A ZA200506549 A ZA 200506549A ZA 200506549 B ZA200506549 B ZA 200506549B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- budesonide
- allergic rhinitis
- mcg
- cyclodextrin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 158
- 239000003246 corticosteroid Substances 0.000 title claims description 12
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 149
- 229960004436 budesonide Drugs 0.000 claims description 140
- 239000000243 solution Substances 0.000 claims description 59
- 239000007864 aqueous solution Substances 0.000 claims description 49
- 238000001556 precipitation Methods 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 25
- 239000006184 cosolvent Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 229920000858 Cyclodextrin Polymers 0.000 claims description 22
- 201000010105 allergic rhinitis Diseases 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 20
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 20
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 20
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 19
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 19
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 19
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims description 19
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 19
- 201000009890 sinusitis Diseases 0.000 claims description 19
- 208000000592 Nasal Polyps Diseases 0.000 claims description 18
- 208000037062 Polyps Diseases 0.000 claims description 18
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 18
- 230000000306 recurrent effect Effects 0.000 claims description 18
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 17
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 230000001476 alcoholic effect Effects 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 11
- 239000008139 complexing agent Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 7
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 6
- 239000004302 potassium sorbate Substances 0.000 claims description 6
- 235000010241 potassium sorbate Nutrition 0.000 claims description 6
- 229940069338 potassium sorbate Drugs 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 235000015424 sodium Nutrition 0.000 claims description 6
- 239000008121 dextrose Substances 0.000 claims description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 229960003339 sodium phosphate Drugs 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 229910021538 borax Inorganic materials 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229940095629 edetate calcium disodium Drugs 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 claims description 2
- 229940099402 potassium metaphosphate Drugs 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 229940037001 sodium edetate Drugs 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 2
- 229960005066 trisodium edetate Drugs 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 239000007921 spray Substances 0.000 description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 238000009472 formulation Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000007726 management method Methods 0.000 description 13
- -1 nipazole Chemical compound 0.000 description 13
- 229920003091 Methocel™ Polymers 0.000 description 9
- 239000007922 nasal spray Substances 0.000 description 9
- 239000008215 water for injection Substances 0.000 description 9
- 229940097496 nasal spray Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 229940097362 cyclodextrins Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010052437 Nasal discomfort Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940072265 rhinocort Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920002302 Nylon 6,6 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940072266 pulmicort Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241001282736 Oriens Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010051496 Rhinalgia Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 231100000568 intoxicate Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Inorganic materials [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 229910001386 lithium phosphate Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940014206 metered dose nasal spray Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
A LOW DOSE CORTICOSTEROID COMPOSITION
The present invention relates to a low dose corticosteroid composition of budesonide said . composition being suitable for administration of budesonide to mucosal membranes. bh)
Particularly the present invention relates to a low dose composition of budesonide suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis comprising budesonide at a therapeutically effective dose of less than 16 mcg and a pharmaceutically acceptable liquid carrier. :
The preferred low dose composition of budesonide suitable for administration of budesonide to the mucosal membranes is a stable aqueous solution composition of budesonide. oC
Budesonide, a synthetic corticosteroid, is an antiinflammatory agent useful for prophylaxis and treatment of asthma, and for treatment of perennial and seasonal allergic rhinitis. It is available in the form of an oral inhalation powder (PULMICORT® TURBUHALER, 200mcg), and oral inhalation suspension (PULMICORT®RESPULES, 0.25mg & 0.5mg) for maintenance treatment of asthma and as prophylactic therapy. For rhinitis, it is available as a metered-dose nasal spray formulation (RHINICORT AQUA, 32mcg) containing budesonide in aqueous suspension and a metered-dose pressurized aerosol unit (RHINOCORT Nasal Inhaler) containing a suspension of 75 micronized budesonide in a mixture of propellants, (dichlorodifluromethane, trichloromonofluromethane and dichlorotetrafluoroethane) and sorbitan trioleate.
Rhinocort nasal inhaler is a metered-dose pressurized aerosol unit, wherein each actuation releases 50 mcg budesonide from the valve and delivers approximately 32 meg budesonide from . 30 the nasal adapter. The recommended starting dose is 256 mcg daily, given as either two sprays in ; each nostril morning and evening and as four sprays in each nostril in the morning. Rhinocort _ aqua, nasal spray 32 mcg, is a metered-dose, manual pump spray formulation, whose recommended starting dose for adults and children 6 years of age and older is. 64 mcg per day administered as one spray per nostril once daily. The maximum recommended dose for adults is
256 mcg per day and for pediatrics is 128 mcg per day.
The Rhinocort aqua, nasal spray 32 mcg, is a metered-dose, manual-pump spray formulation containing a micronized suspension of budesonide in an aqueous medium. Systemic corticosteroid effects such as hypercorticism and adrenal suppression, has been reported to occur with the administration of larger doses of corticosteroids and hence it is recommended to use minimal effective dose of budesonide nasal spray. As mentioned above, for Rhinocort aqua, the recommended starting dose is 64 mcg per day administered as one spray per nostril of the available 32 mcg Nasal spray once daily which may be increased if the patients do not achieve the symptom control but in order to reduce the possibility of side effects it is always desirable to titrate an individual patient to the minimum effective dose.
We have now surprisingly found that a lower metered spray dose of budesonide than that previously recommended is effective for the management of nasal symptoms associated with allergic rhinitis and is also well tolerated when administered intranasaly. Thus we provide a composition comprising budesonide at a therapeutically effective dose of less than 16 mcg and pharmaceutically acceptable liquid carrier such that the composition is suitable for administration of budesonide to the mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis.
United States Application No. US20020016315A1 discloses a metered unit dose comprising 40 meg or less of budesonide, its formulations and its use for the treatment of conditions in the nose.
The patent exemplifies a suspension comprising 32 mcg budesonide. Studies on the marketed preparation Rhinocort® Nasal spray shows that a 32 mcg suspension is efficacious. There is no study or publication demonstrating that doses less than 16 mcg may be also efficacious. We have found novel compositions comprising budesonide at a therapeutically effective dose of less than 16 mcg that are effective in management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis thus meeting the much needed requirement of providing a less dose of a corticosteroid for therapeutic efficacy to reduce B the possibility of side effects.
Thus a low dose composition of budesonide wherein the composition is suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms . associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent . sinusitis wherein the composition comprises of budesonide at a therapeutically effective dose of ~ 5 less than 16 mcg and pharmaceutically acceptable liquid carrier is provided in the present invention. :
Further we have also found an aqueous pharmaceutically acceptable liquid carrier for budesonide wherein budesonide is present in dissolved form and when stored at room temperature for one year there is no precipitation of budesonide over the one-year period. More particularly we also found stable aqueous solution composition of budesonide which are free of alocoholic cosolvents suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non- allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and ‘recurrent sinusitis such that the composition is efficacious and well tolerated when administered at a metered spray dose of less than 16 mcg per nostril.
Further we have also found an aqueous pharmaceutically acceptable liquid carrier for budesonide wherein budesonide is present in dissolved form and when stored at room temperature for one year there is no precipitation of budesonide over the one-year period. More particularly we also found stable aqueous solution composition of budesonide which are free of alocoholic cosolvents suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non- allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and 95 recurrent sinusitis such that the composition is efficacious and well tolerated when administered at a metered spray dose of less than 16 mcg per nostril.
Budesonide, because of its high lipophilicity, is virtually insoluble in water. Hence, there are considerable difficulties in formulating aqueous solutions of budesonide including the need for the addition of solvents like alcohols, to keep the drug in solution. It is however desirable to avoid the use of alcoholic cosolvents. For example in a study reported in Ann Allergy 1988,
Oct;(4):305-310, wherein the study compared the incidence of nasal burning and stinging, as well as overall tolerability of the currently marketed formulation of Rhinalar (flunisolide, marketed formulation) to a new formulation of Rhinlar containing less propylene glycol, the results showed a very significant difference in terms of severity, duration and tolerability in favour of the new . formulation. Moreover the effects of long-term use of preparations containing substantial amount of a cosolvent are not known. Also, United States Patent No. 6,241,969 has stated that there are . limits to acceptable levels of cosolvents included in inhaled products and the limits are set by the
S propensity of these solvents either to cause local irritation of lung tissue and/or to intoxicate the patient. However, the problem associated with aqueous solutions of budesonide free of alcoholic cosolvent is that the drug undergoes decomposition, and because of its low solubility in water, it has a tendency to precipitate on storage at room temperature. It is thus a further object of the present invention to provide stable aqueous solution composition of budesonide characterized in that the composition is free from an alcoholic solvent and when stored at room temperature for one year exhibits no precipitation of budesonide. The said aqueous composition comprises budesonide and a complexing agent and has a pH not exceeding 6.0. Various techniques used in prior art to develop stable budesonide solutions are given below. Patentees in United States Patent No. 5,914,122 disclosed that although prior to their invention budesonide aqueous solutions could be prepared with the help of organic water-soluble alcohols, in these solutions budesonide decomposed within a short time and thus prior to the invention ready to use stable solution preparations of budesonide were not known. The patent claims stable budesonide solution with pH less than 6.0 wherein budesonide is dissolved in a solvent selected from the group consisting of water, alcohol, and a water/alcohol mixture and wherein the alcohol is selected from ethanol, isopropanol and propylene glycol. Alcohol free aqueous solution compositions of budesonide that were stable with respect to chemical decomposition of budesonide as well as free from precipitation of budesonide upon storage at room temperature were not disclosed. The patent further claims that the composition further comprises stabilizing additives selected from sodium EDTA (0.001%-0.1% w/w) and cyclodextrin (0.05%-1.0% by weight).
United States Patent No. 6,241,969 claims aerosolized composition of a corticosteroid to respiratory tract consisting essentially of 5 mcg/ml to 5 mg/ml of the corticosteroid, about 0.1 to about 20% by weight of a high-HLB surfactant component comprising atleast 50% by weight of : an ethoxylated derivative of vitamin E and at least about 70% by weight of an aqueous phase. All B the supportive examples of the composition, however, illustrate compositions that comprise both a high-HLB surfactant as well as a cosolvent like propylene glycol, ethanol, polyethylene glycol etc. Budesonide is one of the corticosteroids further claimed in this patent. The high-HL.B surfactant component exemplified and claimed is tocopheryl polyethylene glycol 1000 succinate. . The invention further discloses addition of excipients such as buffers, osmotic agents, low toxicity antifoaming agents and preservatives. When buffers are used for pH adjustment, the . recommended range is of pH within 4 - 8 and more preferably within 5 - 6.8. The patented composition does not contain any complexing agent that complexes budesonide.
United States Application No. US20020031558A1 claims clear aqueous solutions of bile acids, bile acid derivatives, bile salts or conjugated bile acids, which remain in solution over range of pH values. These aqueous compositions were useful when orally administered for treating gastric and peptic ulcer disease, liver disease, gall stones and hyperlipidemia. The invention thus relates to the therapeutic potential of bile acid, salts, derivatives or conjugates. However it claims in dependent claims also clear solutions as defined above further comprising pharmaceutically effective compounds. The only example supporting this further claim uses bismuth citrate as the pharmaceutically effective compound. According to the claims, the clear aqueous solution may also be administered intranasally. Although budesonide is one of the pharmaceutically effective compounds the patent does not exemplify such compositions and therefore does not address issues such as chemical stabilization of budesonide, or prevention of precipitation of budesonide over a period of time of storage. The disclosed compositions do not contain a complexing agent capable of complexing with budesonide.
PCT Application WO 01/07014 claims a stable formulation for inhalation through nebulization consisting of a solution of a steroid in which (a) the steroid concentrations ranges from 0.01%- 0.1%; (b) the carrier is a mixture of water and propylene glycol in a ratio ranging from 60:40 to 30:70 v/v; and (c) pH is adjusted with concentrated strong acid in a range from 3.5 to 5.0; wherein the percentage of nebulized active ingredient particles with mean aerodynamic diameter below 6pm is higher than 70% and the nebulization efficiency is higher than 20%. Budesonide or its epimers are further claimed as one of the steroids. The inventors found that the solutions adjusted to pH 4 and 4.5 remained stable. The inventors further studied stability of the budesonide solutions by adjusting the pH using buffers consisting of different relative percentages of sodium phosphate and citric acid buffers. They concluded that inclusion of buffers resulted in less stable solutions. A high concentration of an alcoholic solvent like propylene BN glycol used in the disclosed formulation is undesirable for use on mucosal membranes.
Russian Patent No. RU2180217 discloses a stable budesonide solution with an anti-inflammatory - effect that contains budesonide, propylene glycol, polyethylene oxide, benzoic acid, Trilon B, nipazole, thiourea and water. The solution can additionally contain 2-hydroxypropyl-beta- . cyclodextrin.
PCT Publication No. WO 01/87203 claims a stable budesonide solution comprising budesonide and a solvent wherein after about 12 weeks, budesonide is present in solution in an amount at least about 90% preferably at least about 95%, most preferably at least about 99% of the initial budesonide concentration in the solution. The solvent used was generally a non-aqueous solvent such as polyhydric alcohol or glycol, more preferably propylene glycol or triethylene glycol but * water could be added as a cosolvent.
United States Patent No. 6,491,897 claims a stable pharmaceutical budesonide aerosol solution with a pH between 2.0 and 7.0 in which the budesonide is dissolved in a water/ethanol mixture, which mixture optionally includes an alcohol selected from the group consisting of isopropanol and propylene glycol and wherein the stable solution comprises 0.001% to 5% by weight of budesonide. All the disadvantages quoted above with regard to use of alcoholic cosolvents in nasal and pulmonary delivery systems will apply to this patented composition.
United States Patent No. 4,383,992 claims a water-soluble inclusion compound formed by complexing beta-cyclodextrin with a steroid compound having a molecular structure smaller than the inside dimension of the internal cavity of beta-cyclodextrin. Another independent claim claims, an anti-inflammatory pharmaceutical preparation comprising the above inclusion compound mixed with non-toxic pharmaceutical carrier. The example in this patent, teaches the method of forming the inclusion compound of beta-cyclodextrin and the steroids (like, prednisolone acetate or dexamethasone or hydrocortisone) wherein dispersing agent like hydroxypropyl methylcellulose has also been added and a solution obtained. The patent however does not disclose inclusion complex formation of budesonide with beta-cyclodextrin and whether it would provide a stable formulation. Nor does it address issues such as the pH requirement for stabilization of budesonide solutions or the prevention of precipitation of budesonide over a period of time of storage. BN
The objects of the invention are — 1 To provide a low dose corticosteroid composition of budesonide suitable for administration of budesonide to mucosal membranes. : 2) To provide a low dose composition of budesonide suitable for intranasal administration of budesonide for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis wherein the composition comprises of budesonide at a therapeutically effective dose of less than 16 mcg per nostril. 3) To provide a composition as in 2 above wherein the composition comprises "budesonide and pharmaceutically acceptable liquid carrier wherein the liquid carrier is aqueous. 4) To provide an aqueous solution composition of budesonide which is free of alcoholic solvents. 5) To provide an aqueous solution composition of budesonide which is substantially : free of a cosolvent. 6) To provide aforesaid aqueous solution composition of budesonide wherein . 20 : budesonide is stabilized against its chemical decomposition. 7) To provide aforesaid aqueous solution composition where instead of solubilising budesonide with alcoholic cosolvents, the solubilization is achieved by the use of a complexing agent capable of forming a complex with budesonide. 8) To also provide aforesaid aqueous solution composition as in 7 above wherein further the propensity of budesonide to precipitate on long-term storage is inhibited. 2) To provide aqueous solution composition of budesonide baving a low local irritation of mucosal membranes. 10) To provide aqueous solution composition of budesonide having a high availability of budesonide at the site of action. _. 11) To provide an aqueous solution composition of budesonide having a high availability at the site of action and reduced systemic availability of budesonide oT or its metabolites.
12) To provide an aqueous solution composition of budesonide as in 11 above and having a low dose of budesonide. : 13) To provide a method of treatment for management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis by administering budesonide intranasaly at a therapeutically effective dose of less than 16 mcg per nostril. ‘ 14) To provide a method of treatment for management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic : sinusitis and recurrent sinusitis by administration of a stable aqueous solution comprising budesonide in a dissolved form.
15 .
Thus the present invention provides a low dose composition of budesonide suitable for administration of budesonide to mucosal membranes.
The present invention particularly provides a low dose composition of budesonide suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis wherein the composition comprises of budesonide at a therapeutically effective dose of less than 16 mcg and a pharmaceutically acceptable liquid carrier. 25 .
The present invention more particularly provides a low dose composition of budesonide wherein the composition is a stable aqueous solution composition of budesonide said composition being suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non- allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis such that the composition is efficacious and well tolerated when administered at metered spray dose of less than 16 mcg per nostril. :
The said composition comprises budesonide and pharmaceutically acceptable liquid carrier - wherein the liquid carrier is aqueous and budesonide is present in dissolved form and when stored at room temperature for one year there is no precipitation of budesonide over the one-year period. . Particularly the said composition is a stable aqueous solution composition comprising budesonide in an aqueous medium, which is free from an alcoholic cosolvent wherein the medium comprises a complexing agent wherein, said aqueous solution has a pH not exceeding 6.0
Thus a method of treatment for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis in a mammal in need : thereof which comprises intranasal administration of budesonide at a therapeutically effective dose of less than 16 mcg per nostril is provided herewith in the present invention. s DETAILED DESCRIPTION OF THE PRESENT INVENTION
According to the invention we provide a low dose composition comprising budesonide and pharmaceutically acceptable liquid carrier.
We particularly provide an aqueous solution composition of budesonide which is effective when administered at a metered spray dose of less than 16 mcg per nostril said composition being suitable for nasal administration to a mammal in a single dose for the treatment of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non- allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis (both persistent and intermittent).
The therapeutically effective dose may be from 2 mcg to less than 16 mcg per nostril, preferably from 5 mcg to less than 16 mcg per nostril and more preferably from about 8 mcg to about 15 mcg per nostril.
By administering the solution composition of budesonide at such a low metered spray dose, it is possible for the patients to take a lower metered daily dose, which is not only effective for i treatment of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis but is also well tolerated and safe to the nose. The solution composition administered at this dose is also convenient to the patients and thus provides added » advantage of better patient compliance. . Accordingly we provide a therapeutic method of treating nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis by administering into each nostril of a mammal a metered spray dose of less than 16 mcg of a solution composition of budesonide. The dose is administered to each nostril from once-a-day to up to eight times in a day; preferably administered as a metered spray dose of less than 16 meg per nostril per day. More preferably the solution composition is sprayed in each nostril at a dose of 15 mecg/spray once-a-day to achieve the desired effective dose of 30mcg/day.
The stable aqueous solution composition of budesonide is a clear stable aqueous solution administered as intranasal drops or intranasal sprays wherein the recommended lower dose can be administered from a drop pipette or a rhinyl or from nasal inhaler or a spray device. The dose can be administered from unit dose containers or from metered dose spray pumps with varying dose volumes, wherein the concentration of budesonide in the composition is adjusted to give the desired unit dose of budesonide.
In the stable aqueous solution composition of the present invention the budesonide is solubilized ’ in water by complexation with a complexing agent. Preferable the complexing agent is chemical species capable of forming an inclusion complex with budesonide. Preferred inclusion complex forming agents are cyclodextrins. The cyclodextrins that may be used in the present invention is "any of the water-soluble substituted or unsubstituted cyclodextrins or its derivatives thereof which can be well tolerated when administered by nasal, pulmonary or oral route, which is for e.g. a-, B- or y-cyclodextrins or derivatives thereof, preferably derivatives wherein one or more of the hydroxy groups are substituted, e.g. by alkyl, hydroxyalkyl, carboxyalkyl, alkylcarbonyl, carboxyalkoxyalkyl, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl or hydroxy-(mono or polyalkoxy)alkyl groups, wherein each alkyl or alkylene moiety preferably contains up to six carbons. Substituted cyclodextrins, which can be used in the present invention, include ethers, - polyethers or mixed ethers thereof. More preferably such substituted cyclodextrins are ethers B wherein the hydrogen of one or more cyclodextrin hydroxy groups is replaced by one or more cyclodextrin hydroxy groups is replaced by C,salkyl, hydroxy-C,4alkyl or carboxy-C,..alkyl or more particularly by methyl, ethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, carboxymethyl or carboxyethyl. Most preferred cyclodextrins used in the present invention are B-cyclodextrin . ethers and polyethers e.g. dimethyl-f-cyclodextrin, hydroxypropyl- B-cyclodextrin and hydroxyethyl- B-cyclodextrin. In the aqueous solution composition of the present invention, the . cyclodextrin is preferably used at 0.05 % w/v to about 15.0 % w/v, more preferably at 1.0 % w/v to about 10.0 % w/v and most preferably at 1.5 % w/v to about 5.5 % w/v.
In preferred embodiments of the stable aqueous solution composition of present invention hydroxypropyl-B-cyclodextrin is used. Commercially, Hydroxypropyl--cyclodextrin is made by : reacting p-cyclodextrin with propylene oxide, it has a true density of 1.378 g/cm’ and has a cavity diameter of 6.0 - 6.5 A.
The pH of the stable aqueous solution composition of the present invention may be adjusted to less than 6, preferably in the range between about 6.0 and 3.5, more preferably between, 4.0 and 4.5. Examples of suitable pH adjusting agents, selected from a group of buffering agents, comprises lactic acid, citric acid, tartaric acid, phosphoric acid, acetic acid. hydrochloric acid, nitric acid, sodium or potassium metaphosphate, sodium or potassium phosphate, sodium or potassium acetate, ammonia, sodium carbonate, sodium or potassium hydroxide, dibasic sodium phosphate, sodium borate, and the like and mixtures thereof. Adjusting pH using strong mineral acids like hydrochloric acid is more preferred.
A precipitation inhibitor may be included in the stable aqueous solution composition of the present invention. Precipitation inhibitor used in the stable aqueous solution composition of present invention that prevents the precipitation of budesonide from the solution comprises of a primary precipitation inhibitor comprising a water. soluble hydrophilic polymer optionally in mixture with an auxillary precipitation inhibitor comprising solubilizing agents selected from a) cosolvents other than an alcoholic solvent and b) solubilizers selected from anionic, cationic, and/or non-ionic surfactant or mixtures thereof.
The water-soluble hydrophilic polymers used as primary precipitation inhibitor in the stable aqueous solution composition of the present invention includes and are not restricted to cellulose and cellulose derivatives, vinyl pyrrolidone polymers or polyvinylpyrrolidone and polyvinyl _ alcohol. Examples of cellulose and cellulose derivatives that can be used include hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC) and the like. Various grades of hydroxypropyl methylcellulose may be used in the present invention.
The grades available are categorized depending upon the chemical substitution and hydration . rates. Hydroxypropyl methylcellulose having % methoxy content of 19-24 % and hydroxypropyl content of 7-12 % with a fastest relative rate of hydration is available commercially under the “ brand name of Methocel Grade K. Hydroxypropyl methylcellulose with 28-30 % methoxy content and 7-12 % of hydroxypropyl content with a faster relative hydration rate as compared to . the above grade is available commercially under the brand name of Methocel Grade E.
Hydroxypropyl methylcellulose with 27-30 % methoxy content and 4-7.5 % of hydroxypropyl content with a slow relative hydration rate is available as Methocel F grade and that with 27.5- 31.5 % methoxy content and 0 % hydroxypropyl content and with slowest rate of hydration is available as Methocel Grade A. In preferred embodiments of the aqueous solution composition of the present invention, Hydroxypropyl methylcellulose with a viscosity ranging from about 3500 mPas to about 5600 mPas of a 2 % w/v aqueous solution, commercially available as
Methocel E4 is used as the stabilizing primary precipitation inhibitor in an amount ranging from about 0.01 % w/v to about 5.0 % w/v. Even very small quantities of the water-soluble hydrophilic polymer serve to achieve a beneficial precipitation inhibiting effect in the stable aqueous solution composition of the present invention and thus more preferably it is used inan amount ranging from about 0.1 % w/v to about 0.5 % w/v.
Any mucosally non-irritant cosolvent may be used as an auxillary precipitation inhibitor. The cosolvent is used in low quantities and the composition is free from substantial quantity of the cosolvent. A composition that is substantially free of cosolvent and uses less than 5% cosolvent, preferably less than 2% cosolvent is preferred. The more preferred cosolvent is N-methyl pyrrolidone. In preferred embodiments, budesonide may be first dissolved in this dipolar aprotic water-miscible broad-spectrum solubilizer, N-methyl-pyrrolidone, used in an amount just enough to dissolve the drug, i.e in an amount ranging from 0.1 % w/v to about 2.0 % w/v and this drug solution may be added to the cyclodextrin solution and mixed intimately to form the inclusion complex. N-methyl-pyrrolidone has a viscosity of 1.65 mPas at 25°C and is known to increase solubility, rate of solubilization and solution stability of drugs in aqueous solutions. Additionally, when N-methyl pyrrolidone is used nasally it does not cause any nasal irritation or does not change the nasal volume. :
Further the stable aqueous solution composition of the present invention may contain other B conventional pharmaceutical excipients, e.g. osmogens, chelating agents, preservative agents, antioxidants etc.
x Examples of the osmogent(s) that may be used in the stable aqueous solution composition of the present invention include all pharmaceutically acceptable and pharmacologically inert water- . soluble compounds referred to in the pharmacopoeias such as United States Pharmacopoeia, as well as in Remington: The Science and Practice of Pharmacy; edition 19; Mack Publishing
Company, Easton, Pennsylvania (1995). Pharmaceutically acceptable water-soluble salts of inorganic or organic acids, or non-ionic organic compounds with high water solubility, e.g. carbohydrates such as sugar, or amino acids, are generally preferred. The examples of agents used for rendering the solution isoosmotic include inorganic salts such as magnesium chloride or magnesium sulfate, lithium, sodium or potassium chloride, lithium, sodium or potassium : hydrogen phosphate, lithium, sodium or potassium dihydrogen phosphate, salts of organic acids such as sodium or potassium acetate, magnesium succinate, sodium benzoate, sodium citrate or sodium ascorbate; sodium carbonate or sodium bicarbonate; carbohydrates such as mannitol, sorbitol, arabinose, ribose, xylose, glucose, dextrose, fructose, mannose, galactose, sucrose, maltose, lactose, raffinose, inositol, xylitol, maltitol; water-soluble amino acids such as glycine, leucine, alanine, or methionine; urea and the like, and mixtures thereof. Preferred osmogent is dextrose, which may be added in an amount, which renders the solution isoosmotic.
Chelating agents that may be used in the stable aqueous solution composition of the present invention are selected from a group comprising edetic acid, edetic acid salts like disodium edetate, sodium edetate, edetate calcium disodium and trisodium edetate, malic acid and the like and mixtures thereof. :
A preservative agent may be added in the stable aqueous solution composition of the present invention to protect the solution composition from microbial contamination. Examples of such preservatives are benzalkonium chloride, methyl paraben, propyl paraben and their salts, potassium sorbate and sodium benzoate. The preservatives may be present in an amount ranging from about 0.002 to 0.5 % w/w of the formulation. The preferred preservative used in the present invention is potassium sorbate. ’ The stable aqueous solution composition of the present invention may be prepared by a process } wherein budesonide and a complexing agent are mixed in an aqueous medium free from an alcoholic cosolvent to form a solution, other conventional pharmaceutically acceptable excipients are added and the pH is adjusted to less than 6.0. The obtained solutions according to the process may be filled in suitable containers such as multidose vials or preferably in . monodose vials and used in forms such as and not restricted to nasal drops, nasal sprays, metered aerosol, inhalation sprays and the like. The solution compositions may be sterilized when . required by any techniques used in art, preferably by filtration. Additionally, it is preferred that during the manufacturing process exposure to oxygen or oxidative materials, or light be avoided to protect the solution from any potentially ensuing damage.
In a preferred embodiment, the stable aqueous solution composition of the present invention may be prepared by a simple process comprising dissolving budesonide in N-methyl pyrrolidinone and mixing with aqueous dispersion of hydroxypropyl methylcellulose and hydroxypropyl p- cyclodextrin. Dextrose, disodium edetate and potassium sorbate is dissolved in water for injection and mixed with the budesonide solution mixture. Under stirring, the pH of the solution is adjusted using 5 % v/v hydrochloric acid to pH 4.0 — 4.5 and volume made up with water for injection. The solution may be filtered under nitrogen pressure to obtain a clear stable aqueous solution composition of budesonide.
The solution composition of budesonide was administered to patients to evaluate its efficacy and tolerability in comparison to a suspension composition of budesonide, the results of which is discussed in example 5 given below.
The invention is illustrated by the following examples, which is by no means intended to limit the scope of the invention but is given by way of illustration.
Example 1
This example illustrates one embodiment of the present invention and a process for its preparation, formula for which is given in Table 1 below.
Table 1 '$ oo
Hydroxypropyl methylcellulose | 0.250 25 pl A 5S Hydroxypropyl methylcellulose was dispersed in about 40 % of water for injection heated to } 80°C, chilled 25 % water for injection was then added to it after cooling the above solution to 40°C. Hydroxypropyl B-cyclodextrin dissolved in water for injection was added to the the above formed slightly viscous clear solution under stirring. Budesonide dissolved in N-methyl pyrrolidinone was added dropwise under stirring to the above solution. The dextrose, disodium edetate and potassium sorbate was dissolved in 20 % water of injection and added to the drug solution. pH of the resultant solution was adjusted using hydrochloric acid between 4.0 — 4.5 and volume made up with the remaining water for injection. The solution was filtered through 0.22 micron nylon 66 membrane filter using a pre-filter of 2 micron glass fibre and filled into vials.
The solutions were subjected to stability studies by storing in sealed vials at 40°C/75%RH and 25'C/60%RH storage conditions. The initial and 3 months data for the samples are given in Table 2 below.
Table 2
Sn Ml ll al Oc A * (% RS i. content) : I RR IE I EE Tmitial | - | complies | 401 | 10036 | 048
1 3 [| complies [ 38 | 9014
CIGVRE 98.24
LI 3 | complies [ 380 | 9455 (*) complies means complies with the specification and the specification is — clear solutions , without any presipitation. (*#) total RS is total related substances. 5 ' Example 2
This example illustrates another embodiment of the present invention. oo Table 3 orien we [ewion
Hydroxypropyl methylcellulose | 0.2 20 (Methocel E4)
Hydrochloric acid (1% v/v) gstopH4.5-5.0 qs topH 4.0-4.5
Hydroxypropyl methylcellulose was dispersed in about 40 % of water for ‘injection heated to 80°C, chilled 25 % water for injection was then added to it after cooling the above solution to 40°C. Hydroxypropyl B-cyclodextrin dissolved in water for injection was added to the the above formed slightly viscous clear solution under stirring. Budesonide dissolved in N-methyl pyrrolidinone was added dropwise under stirring to the above solution. The disodium edetate and potassium sorbate was dissolved in 20 % water of injection and added to the drug solution. pH of the resultant solution was adjusted using hydrochloric acid between 4.0 - 4.5 and volume made up with the remaining water for injection. The solution was filtered through 0.22 micron nylon 66 membrane filter using a pre-filter of 2 micron glass fibre and filled into vials.
Example 3
This example illustrates another embodiment of the present invention.
Table 4 wom
Hydroxypropyl methylcellulose | 0.25 25 (Methocel E4) :
Atop eos
Hydrochloric acid (1% v/v) qs to pH4.0-4.5 gs to pH4.0-4.5
The process for the preparation of the solution composition was same as that given in example 2.
Example 4
This example illustrates another embodiment of the present invention. . Table 5 gions EL
Hydroxypropyl methylcellulose | 0.25 25 (Methocel E4) . Hydrochloric acid (1% v/v) gs to pH 4.04.5 qstopH4.0-4.5 -
: The process for the preparation of the solution composition was same as that given in example 1. ‘ The solutions were subjected to stability studies by storing in sealed vials at 40°C/75%RH and 25'C/60%RH storage conditions. The initial and 3 months data for the samples are given in Table 6 below.
Table 6 conditions Months | description Assay Total (*) (% RS’ content)
I I I RA I EE mmitial | - | complies [| 400 | 99.36 40 C/75%RH 96.52 ] 3 1 complies [| 367 | 9458 25 C/60%RH 97.61 | 096 1 3 | complies [| 370 [| 97.55 (*) complies means complies with the specification and the specification is — clear solution without any presipitation. (**) total RS is total related substances.
Example 5
This example illustrates another embodiment of the present invention.
Table 7 win
Hydroxypropyl methylcellulose | 0.25 25 (Methocel E4)
Hydrochloric acid (1% v/v) gstopH4.0-4.5 gstopH4.0-45 =
The process for the preparation of the solution composition was same as that given in example 1. 1 | :
Example 6 a
A randomized, parallel-group, multi-center, double-blind, comparative study was performed to evaluate the efficacy and tolerability of two formulations of budesonide nasal spray in allergic rhinitis (persistent or intermittent).
Eighty adults and adolescents (individuals at least 12 years of age) were randomly allocated to either the test formulation of budesonide nasal spray 30 mcg/day (15 mcg/spray in each nostril once-a-day) or reference formulation of budesonide nasal spray 64 mcg/day (32 mcg/spray in each nostril once-a-day).
The formulations were evaluated for primary efficacy (mean change from baseline in total nasal symptom scores (TNSS) and total non-nasal symptom scores (TNNSS) were assessed on day 8, 15, 22 and 29, relief of individual symptoms (viz. sneezing, rhinorrhoea, nasal itching, congestion, ocular itch/burning, watering/tearing, redness of eye), tolerability and overall global assessment in order to determine their clinical efficacy and safety.
The patient assessment of total nasal symptom score is graphically demonstrated in Figure 1 and the non-nasal symptom score is demonstrated in Figure 2.
The results of the study demonstrated that budesonide when administered as an aqueous solution composition was effective in controlling the symptoms of allergic rhinitis at a much lower sprayed dose of 15 mcg/spray in each nostril once-a-day in comparison to a suspension composition of budesonide which demonstrated similar effect at a much higher dose of 32 mcg/spray in each nostril once-a-day. Both the formulations were well tolerated with no side effects.
Claims (32)
1. A low dose corticosteroid composition comprising budesonide and pharmaceutically acceptable liquid carrier suitable for administration of budesonide to the mucosal membranes for the management of nasal symptoms of seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis comprising budesonide at a therapeutically effective dose of less than 16 mcg :
2. A composition as claimed in claim 1 wherein the therapeutically effective dose is from 5 mcg to less than 16 mcg.
3. A composition as claimed in claim 2 wherein the therapeutically effective dose is from about 8 mcg to about 15 mcg.
4. A composition as claimed in claim 1 wherein the pharmaceutically acceptable liquid carrier is aqueous, the budesonide is present in dissolved form and when stored at room temperature : for one year there is no precipitation of budesonide over the one year period.
5. A composition as claimed in claim 4 wherein the stable aqueous solution composition comprises budesonide and a complexing agent capable of forming a complex with budesonide characterized in that the composition is free from an alcoholic cosolvent, has a pH not exceeding 6.0.
6. A composition as claimed in claim 5 wherein the complexing agent is a f-cyclodextrin ether or polyether selected from dimethyl-B-cyclodextrin, hydroxypropyl- B-cyclodextrin, hydroxyethyl- B-cyclodextrin and the like and mixtures thereof.
7. A composition as claimed in claim 6 wherein the B-cyclodextrin used is hydroxypropyl- B- cyclodextrin.
8. A composition as claimed in claim 7 wherein the hydroxypropyl B-cyclodextrin is used in an amount ranging from about 0.05% w/v to about 15.0% w/v.
9. A composition as claimed in claim 8 wherein the hydroxypropyl- B-cyclodextrin is used in an amount ranging from about 1.0% w/v to about 10.0% w/v.
10. A composition as claimed in claim 9 wherein the hydroxypropyl- B-cyclodextrin is used in an amount ranging from about 1.5% w/v to about 5.5% w/v.
11. A composition as claimed in claim 5 further comprising a precipitation inhibitor that prevents the precipitation of budesonide from the solution. BN
12. A composition as claimed in claim 11 wherein the precipitation inhibitor comprises of a primary precipitation inhibitor comprising a water soluble hydrophilic polymer, optionally in mixture with an auxillary precipitation inhibitor comprising solubilizing agents selected from
PCT/IN2004/000042 mix ture with an auxillary precipitation inhibitor comprising solubilizing agents selected from a) cosolvents other than an alcoholic solvent and b) solubilizers selected from anionic, cationic, and/or non-ionic surfactant or mixtures thereof.
13. A composition as claimed in claim 12 wherein the primary precipitation inhibitor comprising a water-soluble hydrophilic polymer is selected from a group of cellulose and cellulose derivatives, vinyl/poly vinyl pyrrolidone polymers, polyvinyl alcohol or mixtures thereof.
14. A composition as claimed in claim 13 wherein the cellulose and cellulose derivatives is selected from hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC) and the like.
15. A composition as claimed in claim 12 wherein the primary precipitation inhibitor is hydroxypropyl methylcellulose.
16. A composition as claimed in claim 15 wherein the hydroxypropyl methylcellulose is having a viscosity in the range from 3500 mPas to about 5600 mPas of a 2% w/w aqueous solution.
17. A composition as claimed in claim 12 wherein the primary precipitation inhibitor is used in an amount ranging from about 0.01% w/v to about 5.0% w/v.
18. A composition as claimed in claim 12 wherein the cosolvent other than alcoholic solvent is N-methyl pyrrolidone.
19. A composition as claimed in claim 5 which further comprises a chelating agent.
20. A composition as claimed in claim 19 wherein the chelating agent is selected from a group comprising edetic acid, edetic acid salts like disodium edetate, sodium edetate, edetate calcium disodium and trisodium edetate, malic acid and the like and mixtures thereof.
21. A composition as claimed in claim 5 wherein further dextrose is used as an osmogent.
22. A composition as claimed in claim 5 wherein further potassium sorbate is used as a preservative.
23. A composition as claimed in claim 5 wherein the aqueous solution having a pH not exceeding 6.0 comprises a buffering agent.
24. A composition as claimed in claim 23 wherein the buffering agent is selected from a group comprising lactic acid, citric acid, tartaric acid, phosphoric acid, acetic acid, hydrochloric acid, nitric acid, sodium or potassium metaphosphate, sodium or potassium phosphate, sodium or potassium acetate, ammonia, sodium carbonate, sodium or potassium hydroxide, dibasic sodium phosphate; sodium borate, and the like and mixtures thereof.
25. Use of budesonide for the preparation of a composition for the management of nasal symploms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non- allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis 21 AMENDED SHEET
PCT/IN2004/000042 : and recurrent sinusitis for intranasal administration of budesonide at a therapeutically effective dose of less than 16 mcg.
26. Use as defined in 25 wherein the therapeutically effective dose is from 5 meg to less than 16 mcg.
27. Use as defined in 26 wherein the therapeutically effective dose is from about 8 mcg to about meg.
28. Use as defined in 25 wherein the composition is such that it is suitable for administration of budesonide to the mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis.
29. Use as defined in 28 wherein the composition is a stable aqueous solution composition.
30. A composition for use in a method of treatment according to any one of claims 1 to 24, substantially as herein described and illustrated.
31. Use according to any one of claims 25 to 29, substantially as herein described and illustrated.
32. A composition for a new use in a method of treatment, or a new use of budesonide as defined in any one of claims 25 to 29, substantially as herein described. 22 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN197MU2003 | 2003-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200506549B true ZA200506549B (en) | 2006-06-28 |
Family
ID=36605961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200506549A ZA200506549B (en) | 2003-02-17 | 2005-08-16 | A low dose corticosteroid composition |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1750810A (en) |
ZA (1) | ZA200506549B (en) |
-
2004
- 2004-02-16 CN CNA2004800044324A patent/CN1750810A/en active Pending
-
2005
- 2005-08-16 ZA ZA200506549A patent/ZA200506549B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1750810A (en) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060193783A1 (en) | Low dose corticosteroid composition | |
EP2075000B1 (en) | Combination of azelastine and ciclesonide | |
JP5683719B2 (en) | Bepotastine composition | |
US20070148192A1 (en) | Stable ophthalmic composition | |
EP1605932B1 (en) | Intranasal formulation of rotigotine | |
US20060120967A1 (en) | Solution forms of cyclodextrins for nasal or throat delivery of essential oils | |
JP2017206560A (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
US10517880B2 (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
US7378082B1 (en) | Method for treating allergic rhinitis without adverse effects | |
EP1250925B1 (en) | Nasal spray containing ondansetron hydrochloride | |
US20070099883A1 (en) | Anhydrous mometasone furoate formulation | |
US20150250718A1 (en) | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | |
US20120022032A1 (en) | Corticosteroid compositions and methods of treatments thereof | |
KR20140003504A (en) | Liquid propellant-free formulation comprising an antimuscarinic drug | |
ZA200506549B (en) | A low dose corticosteroid composition | |
EP3725298A1 (en) | Stable and preserved pharmaceutical compositions of bilastine | |
JP2006131619A (en) | Aqueous suspension for nasal drop | |
TW202228690A (en) | Liquid formulations of indacaterol | |
CN114632075A (en) | Voriconazole aerosol inhalation and application | |
EP1698327A1 (en) | Stable pharmaceutical compositions of itraconazole in aqueous environment |